Adult stem cells

Phase 2Cell therapy

TThe University of Texas Health Science Center, Houston

Adult stem cells is one of 25 biologic programs targeting Ischemic Cardiomyopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic CardiomyopathyActive, not recruiting

Peripheral Vascular DiseaseActive, not recruiting

Ischemic CardiomyopathyPhase 2

Active, not recruiting

Peripheral Vascular DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Ischemic Cardiomyopathy

#DrugCompanyPhaseTrials

Calan

VVal Adams

Approved

1 2

Atorvastatin Calcium

Merck & Co.

Approved

1 3

Steglatro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 4

RANEXA

Gilead

Approved

1 5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 6

Victoza

Novo Nordisk

Preclinical

1 7

Aldactone

Pfizer

Preclinical

1 8

Zinc Acetate

NNobelpharma

Phase 1

1 9

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Phase 1

1 10

Adult stem cells

TThe University of Texas Health Science Center, Houston

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Attack2 trials

Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study)

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00684021·120 enrolled

Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00684060·87 enrolled

Peripheral Vascular Disease1 trial

Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease

Unknown status·—·Phase 1·NCT00113243·20 enrolled

Ischemic Cardiomyopathy1 trial

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

Completed·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00824005·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Adult stem cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adult stem cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adult stem cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: TThe University of Texas Health Science Center, Houston

Adult stem cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Attack2 trials

Peripheral Vascular Disease1 trial

Ischemic Cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News